PURPOSE: To determine the potential role for adjuvant proton-based radiotherapy (PT) for resected pancreatic head cancer. METHODS AND MATERIALS: Between June 2008 and November 2008, 8 consecutive patients with resected pancreatic head cancers underwent optimized intensity-modulated radiotherapy (IMRT) treatment planning. IMRT plans used between 10 and 18 fields and delivered 45 Gy to the initial planning target volume (PTV) and a 5.4 Gy boost to a reduced PTV. PTVs were defined according to the Radiation Therapy Oncology Group 9704 radiotherapy guidelines. Ninety-five percent of PTVs received 100% of the target dose and 100% of the PTVs received 95% of the target dose. Normal tissue constraints were as follows: right kidney V18 Gy to <70%; left kidney V18 Gy to <30%; small bowel/stomach V20 Gy to <50%, V45 Gy to <15%, V50 Gy to <10%, and V54 Gy to <5%; liver V30 Gy to <60%; and spinal cord maximum to 46 Gy. Optimized two- to three-field three-dimensional conformal proton plans were retrospectively generated on the same patients. The team generating the proton plans was blinded to the dose distributions achieved by the IMRT plans. The IMRT and proton plans were then compared. A Wilcoxon paired t-test was performed to compare various dosimetric points between the two plans for each patient. RESULTS: All proton plans met all normal tissue constraints and were isoeffective with the corresponding IMRT plans in terms of PTV coverage. The proton plans offered significantly reduced normal-tissue exposure over the IMRT plans with respect to the following: median small bowel V20 Gy, 15.4% with protons versus 47.0% with IMRT (p = 0.0156); median gastric V20 Gy, 2.3% with protons versus 20.0% with IMRT (p = 0.0313); and median right kidney V18 Gy, 27.3% with protons versus 50.5% with IMRT (p = 0.0156). CONCLUSIONS: By reducing small bowel and stomach exposure, protons have the potential to reduce the acute and late toxicities of postoperative chemoradiation in this setting.
PURPOSE: To determine the potential role for adjuvant proton-based radiotherapy (PT) for resected pancreatic head cancer. METHODS AND MATERIALS: Between June 2008 and November 2008, 8 consecutive patients with resected pancreatic head cancers underwent optimized intensity-modulated radiotherapy (IMRT) treatment planning. IMRT plans used between 10 and 18 fields and delivered 45 Gy to the initial planning target volume (PTV) and a 5.4 Gy boost to a reduced PTV. PTVs were defined according to the Radiation Therapy Oncology Group 9704 radiotherapy guidelines. Ninety-five percent of PTVs received 100% of the target dose and 100% of the PTVs received 95% of the target dose. Normal tissue constraints were as follows: right kidney V18 Gy to <70%; left kidney V18 Gy to <30%; small bowel/stomach V20 Gy to <50%, V45 Gy to <15%, V50 Gy to <10%, and V54 Gy to <5%; liver V30 Gy to <60%; and spinal cord maximum to 46 Gy. Optimized two- to three-field three-dimensional conformal proton plans were retrospectively generated on the same patients. The team generating the proton plans was blinded to the dose distributions achieved by the IMRT plans. The IMRT and proton plans were then compared. A Wilcoxon paired t-test was performed to compare various dosimetric points between the two plans for each patient. RESULTS: All proton plans met all normal tissue constraints and were isoeffective with the corresponding IMRT plans in terms of PTV coverage. The proton plans offered significantly reduced normal-tissue exposure over the IMRT plans with respect to the following: median small bowel V20 Gy, 15.4% with protons versus 47.0% with IMRT (p = 0.0156); median gastric V20 Gy, 2.3% with protons versus 20.0% with IMRT (p = 0.0313); and median right kidney V18 Gy, 27.3% with protons versus 50.5% with IMRT (p = 0.0156). CONCLUSIONS: By reducing small bowel and stomach exposure, protons have the potential to reduce the acute and late toxicities of postoperative chemoradiation in this setting.
Authors: Ted C Ling; Jerry M Slater; Rachel Mifflin; Prashanth Nookala; Roger Grove; Anh M Ly; Baldev Patyal; Jerry D Slater; Gary Y Yang Journal: J Gastrointest Oncol Date: 2015-04
Authors: Richard Y Lee; Romaine C Nichols; Soon N Huh; Meng W Ho; Zuofeng Li; Robert Zaiden; Ziad T Awad; Bestoun Ahmed; Bradfors S Hoppe Journal: J Gastrointest Oncol Date: 2013-12
Authors: Rovel J Colaco; Romaine Charles Nichols; Soon Huh; Nataliya Getman; Meng Wei Ho; Zuofeng Li; Christopher G Morris; William M Mendenhall; Nancy P Mendenhall; Bradford S Hoppe Journal: J Gastrointest Oncol Date: 2014-02
Authors: Nikhil Yegya-Raman; Mihir M Shah; Miral S Grandhi; Elizabeth Poplin; David A August; Timothy J Kennedy; Usha Malhotra; Kristen R Spencer; Darren R Carpizo; Salma K Jabbour Journal: Ann Pancreat Cancer Date: 2018-08-06
Authors: Michael Chuong; Shahed N Badiyan; Man Yam; Zuofeng Li; Katja Langen; William Regine; Christopher Morris; James Snider; Minesh Mehta; Soon Huh; Michael Rutenberg; Romaine C Nichols Journal: J Gastrointest Oncol Date: 2018-08
Authors: Anna Lee; Jung J Kang; Havah Bernstein; Kathryn E Marqueen; Brian Neal; Ciara M Kelly; Mark A Dickson; Chiaojung Jillian Tsai; William Tap; Samuel Singer; Kaled Alektiar; Nancy Y Lee Journal: Cancer Med Date: 2021-06-04 Impact factor: 4.711
Authors: Whoon Jong Kil; R Charles Nichols; John W Kilkenny; Soon Y Huh; Meng Wei Ho; Pratibha Gupta; Robert B Marcus; Daniel J Indelicato Journal: Radiat Oncol Date: 2012-10-26 Impact factor: 3.481